Efficacy and Safety of Patient-Led Dosage Adjustments of Insulin Glargine: A Preliminary Report of Basal-Supported Oral Therapy for Japanese Type 2 Diabetes Patients


To evaluate the clinical utility for simple patient administered dose adjustment methods of insulin glargine during outpatient visits compared with a physician managed titration, changes in HbA1c and total daily dose of insulin were evaluated in 23 patients by dividing patients into physician-led (PL) group and self-titration (ST) group who were newly administered glargine basal-supported oral therapy (BOT) while continuing oral antidiabetic drugs at the discretion of their attending physician during regular outpatient visits. In the PL group, one month after initiation of glargine, HbA1c followed a declining trend, although this was not significant (P = 0.07), and decreased significantly after two and three months (P < 0.05, respectively). However, after 12 months, the significant difference had disappeared. By contrast, in the ST group, HbA1c did not significantly decrease one month after initiation of glargine, but did drop markedly after two and three months, with this trend continuing up to 12 months (P < 0.005). On examining the differences between both groups, we found that the initial dose was significantly larger in the PL group (P < 0.05), whereas the dose increased significantly more in the ST group after three months. While the insulin dose after 12 months was large in the ST group, no statistically significant difference was noted between the two groups (P = 0.14) whereas HbA1c was significantly low in the ST group. In conclusion, we believe that patient-led basal insulin dosage adjustment is an effective and useful therapeutic option when they can master self-monitoring of blood glucose.

Share and Cite:

Nakanishi, S. , Kubota, M. and Kishimoto, R. (2014) Efficacy and Safety of Patient-Led Dosage Adjustments of Insulin Glargine: A Preliminary Report of Basal-Supported Oral Therapy for Japanese Type 2 Diabetes Patients. Journal of Diabetes Mellitus, 4, 77-84. doi: 10.4236/jdm.2014.42014.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] Del Pratos, S., Felton, A.M., Munro, N., Nesto, R., Zimmet, P., et al. (2005) Improving Glucose Management: Ten Steps to Get More Patients with Type 2 Diabetes to Glycaemic Goal. International Journal of Clinical Practice, 59, 1345-1355. http://dx.doi.org/10.1111/j.1742-1241.2005.00674.x
[2] Kadowaki, T., Ohtani, T. and Odawara, M. (2013) Baseline Predictive Factors for Glycemic Control in Japanese Type 2 Diabetes Patients Treated with Insulin Glargine plus Oral Antidiabetic Drugs: ALOHA Study Subanalysis. Diabetology International, 4, 16-22. http://dx.doi.org/10.1007/s13340-012-0087-6
[3] Kawamori, R., et al. (2009) Baseline Characteristics of People with Type 2 Diabetes on Insulin in Japan Compared to the Global Population: Data from the CREDIT Study. IDF 2009, 20th World Diabetes Congress, Montreal, 18-22 October 2009, 341.
[4] Otani, T., et al. (2011) The Safety and Usefulness of BOT (Basal supported Oral Therapy) Using Insulin (ALOHA Study)—Based on the Result of the Lantus® Drug Use Survey “Investigation of the Concomitant Use of Oral Hypoglycemic Drugs (Type 2 Diabetes). Journal of New Remedies and Clinics, 60, 458-475. (in Japanese)
[5] Ishii, H., Iwamoto, Y., Tajima, N., et al. (2012) An Exploration of Barriers to Insulin Initiation for Physicians in Japan: Findings from the Diabetes Attitudes, Wishes And Needs (DAWN) JAPAN Study. PLoS One, 7, e36361.
[6] Japan Diabetes Clinical Data Management Study Group (2007) The Current State of Therapy at Specialist Diabetes Facilities Based on CoDiC® Data Analysis (2). Japanese Journal of Diabetes Master Clinicians, 5, 401-406. (in Japanese)
[7] Korytkowski, M. (2002) When Oral Agents Fail: Practical Barriers to Starting Insulin. International Journal of Obesity Related Metabolic Disorders, 26, 18-24.
[8] Cryer, P. and Childs, B.P. (2002) Negotiating the Barrier of Hypoglycemia in Diabetes. Diabetes Spectrum, 15, 20-27.
[9] Cryer, P. (1999) Hypoglycemia Is the Limiting Factor in the Management of Diabetes. Diabetes Metabolism Research and Reviews, 15, 42-46.
[10] Bolli, G.B. (1989) The Pharmacokinetic Basis of Insulin Therapy in Diabetes Mellitus. Diabetes Research and Clinical Practice, 6, S3-S16. http://dx.doi.org/10.1016/0168-8227(89)90073-9
[11] Lepore, M., Pampanelli, S., Fanelli, C., Porcellati, F., Bartocci, L., et al. (2002) Pharmacokinetics and Pharmacodynamics of Subcutaneous Injection of Long-Acting Human Insulin Analog Glargine, NPH Insulin, and Ultralente Human Insulin and Continuous Subcutaneous Infusion of Insulin Lispro. Diabetes, 49, 2142-2148.
[12] Yki-Jarvinen, H. (2004) Insulin Therapy in Type 2 Diabetes: Role of the Long-Acting Insulin Glargine Analogue. European Journal of Clinical Investigation, 34, 410-416. http://dx.doi.org/10.1111/j.1365-2362.2004.01356.x
[13] Ratner, R. (2003) Insulin Glargine versus NPH Insulin in Patients with Type 1 Diabetes. Drugs Today, 39, 867-876.
[14] Hermansen, K., Fontaine, P., Kukolja, K., Peterkova, V., Leth, G., et al. (2004) Insulin Analogues (Insulin Detemir and Insulin Aspart) versus Traditional Human Insulins (NPH Insulin and Regular Human Insulin) in Basal-Bolus Therapy for Patients with Type 1 Diabetes. Diabetologia, 47, 622-629. http://dx.doi.org/10.1007/s00125-004-1365-z
[15] Chapman, T., Noble, S. and Goa, K.L. (2002) Insulin Aspart: A Review of Its Use in the Management of Type 1 and 2 Diabetes Mellitus. Drugs, 62, 1945-1981. http://dx.doi.org/10.2165/00003495-200262130-00014
[16] Davies, M., Storms, F., Shutler, S., Bianchi-Biscay, M. and Gomis, R. (2005) Improvement of Glycemic Control in Subjects with Poorly Controlled Type 2 Diabetes: Comparison of Two Treatment Algorithms Using Insulin Glargine. Diabetes Care, 28, 1282-1288. http://dx.doi.org/10.2337/diacare.28.6.1282
[17] Odawara, M., Ohtani, T. and Kadowaki, T. (2012) Dosing of Insulin Glargine to Achieve the Treatment Target in Japanese Type 2 Diabetes on a Basal Supported Oral Therapy Regimen in Real Life: ALOHA Study Subanalysis. Diabetes Technology and Therapeutics, 14, 635-643. http://dx.doi.org/10.1089/dia.2011.0220
[18] Nathan, D.M., Buse, J.B., Davidson, M.B., Ferrannini, E., Holman, R.R., et al. (2009) Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy. Diabetes Care, 32, 193-203. http://dx.doi.org/10.2337/dc08-9025
[19] Holman, R.R., Thorne, K.I., Farmer, A.J., Davies, M.J., Keenan, J.F., et al. (2007) Addition of Biphasic, Prandial, or Basal Insulin to Oral Therapy in Type 2 Diabetes. New England Journal of Medicine, 357, 1716-1730.
[20] Hermansen, K., Mortensen, L.S. and Hermansen, M.L. (2008) Combining Insulins with Oral Antidiabetic Agents: Effect on Hyperglycemic Control, Markers of Cardiovascular Risk and Disease. Vascular Health and Risk Management, 4, 561-574.
[21] Khunti, K., Srinivasan, B.T., Shutler, S. and Davies, M.J. (2010) Effect of Insulin Glargine on Glycaemic Control and Weight in Obese and Non-Obese People with Type 2 Diabetes: Data from the AT.LANTUS Trial. Diabetes Obesity and Metabolism, 12, 683-688. http://dx.doi.org/10.1111/j.1463-1326.2010.01217.x
[22] Riddle, M.C., Rosenstock, J. and Gerich, J. (2003) The Treat-to-Target Trial: Randomized Addition of Glargine or Human NPH Insulin to Oral Therapy of Type 2 Diabetic Patients. Diabetes Care, 26, 3080-3086.
[23] Emerging Risk Factors Collaboration, Seshasai, S.R., Kaptoge, S., Thompson, A., Di Angelantonio, E., et al. (2011) Diabetes Mellitus, Fasting Glucose, and Risk of Cause-Specific Death. New England Journal of Medicine, 364, 829-841. http://dx.doi.org/10.1056/NEJMoa1008862
[24] Meier, J.J., Pennartz, C., Schenker, N., Menge, B.A., Schmidt, W.E., et al. (2013) Hyperglycaemia Is Associated with Impaired Pulsatile Insulin Secretion: Effect of Basal Insulin Therapy. Diabetes, Obesity and Metabolism, 15, 258-263.
[25] ATLAS Study Group (2011) Titration of Insulin Glargine in Patients with Type 2 Diabetes Mellitus in Asia: Physician-versus Patient-Led? Rationale of the Asian Treat to Target Lantus Study (ATLAS). Diabetes Technology and Therapeutics, 13, 67-72. http://dx.doi.org/10.1089/dia.2010.0170
[26] Origin Trial Investigators, Gerstein, H., Yusuf, S., Riddle, M.C., Ryden, L., et al. (2008) Rationale, Design, and Baseline Characteristics for a Large International Trial of Cardiovascular Disease Prevention in People with Dysglycemia: The ORIGIN Trial (Outcome Reduction with an Initial Glargine Intervention). American Heart Journal, 155, 26-32.
[27] Aschner, P., Chan, J., Owens, D.R., Picard, S., Wang, E., et al. (2012) Insulin Glargine versus Sitagliptin in Insulin-Naive Patients with Type 2 Diabetes Mellitus Uncontrolled on Metformin (EASIE): A Multicentre, Randomised Open-Label Trial. Lancet, 379, 2262-2269. http://dx.doi.org/10.1016/S0140-6736(12)60439-5

Copyright © 2022 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.